Companies To Watch

  1. Companies To Watch: argenx 5/1/2020

    Argenx is developing new antibody therapeutics for immunological diseases in the neuromuscular, hematology, oncology, and other areas. The company has a full pipeline of candidates and indications.

  2. Companies To Watch: Neurana 4/1/2020

    This 10-person startup in San Diego is aiming for muscle-spasm relief without sedation in a purified drug.

  3. Companies To Watch: Adaptive Phage Therapeutics 2/28/2020

    Adaptive Phage Therapeutics has created a large catalog of bacteria-killing viruses combined with a diagnostic test to identify and target specific bacterial strains infecting individual patients.

  4. Companies To Watch: Imago BioSciences 1/31/2020

    In developing a new drug for MPN diseases, Imago is entering a space where two potential competitors, Jakafi and Inrebic, both JAK (janus associated kinase) inhibitors, are already on the market.

  5. Companies To Watch: Scynexis 12/30/2019

    Scynexis is creating multiple development programs and a new class of antifungals — all in a single, and singular, drug.

  6. Companies To Watch: Obsidian Therapeutics 11/1/2019

    Obsidian Therapeutics targets gene and cell therapies with a technology designed to control the production and activity of therapeutic proteins those therapies induce.

  7. Companies To Watch: eXIthera 10/1/2019

    This month’s company to watch is eXIthera, which is focused on inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants.

  8. Companies To Watch: Leading Biosciences 8/30/2019

    Leading Biosciences is applying the science of digestive proteases to treating or preventing multiple diseases and conditions, starting with delayed return of post-surgical bowel function (ileus) and adhesion with its lead product candidate, coded LB1148.

  9. Companies To Watch: Bioharmony Therapeutics 8/1/2019

    Bioharmony Therapeutics is developing novel, “lysin-based” antimicrobials. The company is out to change the world of antibiotics, not by tweaking an old formula, but by advancing an entirely new mode of action.

  10. Companies To Watch: Angion 7/1/2019

    Angion is developing a small molecule mimetic of the hepatocyte growth factor (HGF), which works to protect kidney and other organ cells from damage due to disease, physical injury, and indirect consequences of surgery and trauma.